Similar articles

• [Efficacy and safety in chronic hepatitis B adolescent patients with lamivudine therapy].

  Lu WL, Xie DY, Yao JL, Yao GB, Cui ZY, Zhang DF, Wu L. Lu WL, et al. Zhonghua Gan Zang Bing Za Zhi. 2004 Jul;12(7):429-31. Zhonghua Gan Zang Bing Za Zhi. 2004. PMID: 15268810 Clinical Trial. Chinese.
• Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients.

  Nikolaidis NL, Giouleme OI, Tziomalos KA, Saveriadis AS, Grammatikos N, Doukelis P, Voutsas AD, Vassiliadis T, Patsiaoura K, Orfanou-Koumerkeridou E, Balaska A, Eugenidis NP. Nikolaidis NL, et al. J Gastroenterol Hepatol. 2005 Nov;20(11):1721-5. doi: 10.1111/j.1440-1746.2005.04029.x. J Gastroenterol Hepatol. 2005. PMID: 16246192 Clinical Trial.
• Changing landscape of antiviral resistance management in chronic hepatitis B.

  Nguyen T, Locarnini S, Desmond P. Nguyen T, et al. J Gastroenterol Hepatol. 2008 Sep;23(9):1314-7. doi: 10.1111/j.1440-1746.2008.05551.x. J Gastroenterol Hepatol. 2008. PMID: 18853991 No abstract available.
• [Treatment and selection criteria for chronic hepatitis B].

  Gunji T, Omata M. Gunji T, et al. Nihon Rinsho. 2004 Aug;62 Suppl 8:309-12. Nihon Rinsho. 2004. PMID: 15453336 Review. Japanese. No abstract available.
• Hepatitis B virus infection--natural history and clinical consequences.

  Ganem D, Prince AM. Ganem D, et al. N Engl J Med. 2004 Mar 11;350(11):1118-29. doi: 10.1056/NEJMra031087. N Engl J Med. 2004. PMID: 15014185 Review. No abstract available.